Skye Bioscience Average Analyst Price Target Raised 10.29% to $61.20
The average one-year price target for Skye Bioscience (NASDAQCM:SKYE) has been revised to $61.20 / share. This is an increase of 10.29% from the prior estimate of $55.49 dated August 25, 2026. These figures represent aggregate analyst targets compiled from multiple sources and do not constitute a recommendation orinvestment adviceby Fintel. The latest targets range from a low of $16.16 to a high of $168.00 / share, leaving the target range width unchanged at $151.84. The average price target represents an increase of 2,975.38% from the latest reported closing price of $1.99 / share on September 14, 2026.
Looking at the historical progression of the consensus target, the mean target was recorded at $61.20 on September 15, 2026, which is also the observed twelve-month high mean. This follows a mean target of $55.49 on August 28, 2026, $7.48 on August 4, 2026, which is the observed twelve-month low mean, and $7.87 on June 30, 2026. The consecutive target revision direction has increased for 2 consecutive counts. This represents a target change of +677.78% since the 90-day baseline date of June 8, 2026. The current median target remains unchanged at $32.64, resulting in a current mean-median gap of $28.56.
In terms of price performance, Skye Bioscience's stock price closed at $1.99 on September 14, 2026. This represents a one-week price change of +6.99% from the baseline close of $1.86 on September 4, 2026, and a one-month price change of +296.89% from the baseline close of $0.50 on August 14, 2026. For its latest earnings reported on August 14, 2026, the company reported an actual EPS of -1.68, compared to the estimated EPS of -2.0144. Actual revenue was reported at $0.00, which matched the revenue estimate of $0.00.
Skye Bioscience is classified under the Financials GICS sector, Capital Markets industry, and Asset Management & Custody Banks sub-industry. Within this sub-industry, 31 companies are covered, with 12 companies raised, 6 lowered, and 13 unchanged. The sub-industry median revision percent is 0.00%, and the median implied change percent is +18.83%. As of the September 1, 2026 recommendation period, the company had 12 total recommendations, consisting of 2 strong buy, 7 buy, 3 hold, 0 sell, and 0 strong sell recommendations. This represents a positive recommendation percentage of 75.0% and a hold percentage of 25.0%. In the prior period of August 1, 2026, there were 13 total recommendations, with 3 strong buy, 7 buy, 3 hold, 0 sell, and 0 strong sell recommendations, representing a positive percentage of 76.9% and a hold percentage of 23.1%.
Several peer companies in the clinical-stage biopharmaceutical space focusing on GPCR targets or metabolic diseases also saw revisions to their analyst targets. These peers include Structure Therapeutics Inc. - Depositary Receipt, Septerna, and MBX Biosciences. The peer group generally experienced upward revisions in their mean targets, with Septerna leading the group in target revision percentage.
| Company name | Target revision | Implied change |
|---|---|---|
| Structure Therapeutics Inc. - Depositary Receipt | +0.27% | +184.49% |
| Septerna | +19.89% | +41.85% |
| MBX Biosciences | +9.95% | +51.57% |
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.